PALI - צמיחת הכנסות שנתית ב-12 החודשים האחרונים Palisade Bio, Inc.

סמל מסחרי של palisadebio.com (PALI)

Risks for Palisade Bio, Inc. (PALI) stem from a dependence on a single project and a shortage of research funding. However, strong pricing power within the gastrointestinal protease inhibitor niche supports the share price. The current balance sheet relies on external loans due to liquidity burn. This chart of trailing 12-month sales volume dynamics versus the prior year reflects a business maturity phase, where the metric has plateaued at 0.00.

צמיחת מכירות משנה לשנה (TTM): Palisade Bio (PALI) עבור 11.02.2024 - 17.11.2026

Palisade Bio Inc. (PALI) - פילוחי מדדים ודוחות פיננסיים

- מחיר מניה ומחיר יעד קונצנזוס:
הערכת שווי פונדמנטלית של החברה:Palisade Bio
סחורת הדגל של Palisade Bio

This indicator reflects daily revenue dynamics over the last 12 months, capturing the deviation of current sales volumes from the same period last year to identify operational cycles. An analysis of the LTM sales growth YoY metric with a value of 0.00 confirms that Palisade Bio, Inc. lacks commercial products, as its viability in the gastroenterology sector currently relies entirely on external funding.